RVNC Revance Therapeutics Inc.

11.57
0  0%
Previous Close 11.57
Open
Price To Book 2.31
Market Cap 509,156,131
Shares 44,006,580
Volume 0
Short Ratio
Av. Daily Volume 376,748

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completion of enrolment due 2H 2019.
DAXI (RT002)
Plantar fasciitis
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines
Phase 3 completion of enrolment due 2H 2019.
DAXI (RT002) - ASPEN
Cervical dystonia
BLA filing due fall of 2019.
DAXI (RT002)
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated in 2019 or 2020.
DAXI (RT002)
Chronic migraine
Phase 2 completion of enrolment due 2H 2019.
DAXI (RT002)
Upper limb spasticity

Latest News

  1. Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors
  2. Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference
  3. Edited Transcript of RVNC earnings conference call or presentation 8-May-19 8:30pm GMT
  4. Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference
  5. Revance Therapeutics (RVNC) Q1 2019 Earnings Call Transcript
  6. Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update
  7. Is Revance Therapeutics Inc (RVNC) A Good Stock To Buy?
  8. A Spotlight On Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Fundamentals
  9. Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know
  10. Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019
  11. Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing
  12. SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference
  13. Maker of Botox alternative turns toxin on crippling muscle disorder
  14. Revance to Participate in the Needham Healthcare Conference
  15. Does Revance Therapeutics, Inc. (NASDAQ:RVNC) Have A Volatile Share Price?
  16. New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  17. Revance to Participate in Upcoming Investor Conferences
  18. Edited Transcript of RVNC earnings conference call or presentation 26-Feb-19 9:30pm GMT
  19. Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018
  20. Need To Know: Revance Therapeutics, Inc. (NASDAQ:RVNC) Insiders Have Been Buying Shares